| Code | CSB-RA624104MB12HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Xeligekimab, targeting interleukin-17A (IL-17A), a pro-inflammatory cytokine central to immune-mediated pathology. IL-17A is primarily produced by Th17 cells and plays a critical role in host defense against extracellular pathogens while also driving chronic inflammatory responses. Dysregulated IL-17A signaling contributes to the pathogenesis of multiple autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis. By neutralizing IL-17A, this antibody blocks its interaction with IL-17 receptors, thereby inhibiting downstream inflammatory cascades involving neutrophil recruitment and pro-inflammatory cytokine production.
Xeligekimab represents a therapeutic antibody designed to selectively inhibit IL-17A activity in inflammatory disease contexts. This biosimilar provides researchers with a cost-effective tool for investigating IL-17A-mediated mechanisms in autoimmune disease models, studying Th17 cell biology, evaluating cytokine neutralization strategies, and exploring novel therapeutic approaches for inflammatory disorders. It serves as a valuable reagent for immunological research and preclinical studies examining IL-17A pathway modulation.
There are currently no reviews for this product.